Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (261-270 of 391) with videos related to

Pageof 40
Sort By:
American Journal of Respiratory and Critical Care Medicine|June 6, 2022
Genome-wide Enrichment of <i>TERT</i> Rare Variants in Idiopathic Pulmonary Fibrosis Patients of Latino AncestryDavid Zhang, Gundula Povysil, Chad A Newton, et al.
The Lancet. Respiratory Medicine|January 18, 2024
Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trialZhe Wu, Lisa G Spencer, Winston Banya, et al.
The European Respiratory Journal|February 22, 2020
Predictors of progression in systemic sclerosis patients with interstitial lung diseaseOliver Distler, Shervin Assassi, Vincent Cottin, et al.
BMJ Open Respiratory Research|September 14, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)Toby M Maher, Shervin Assassi, Arata Azuma, et al.
The Lancet. Respiratory Medicine|November 14, 2022
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trialToby M Maher, Veronica A Tudor, Peter Saunders, et al.
The European Respiratory Journal|March 30, 2019
In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortalityJohn A Mackintosh, Sujal R Desai, Huzaifa Adamali, et al.
BMJ Open|June 4, 2021
Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility studyClaire M Nolan, Suhani Patel, Ruth E Barker, et al.
Biorxiv : the Preprint Server for Biology|June 10, 2024
Association between mosaic loss of chromosome Y and pulmonary fibrosis susceptibility and severityDapeng Wang, Niran Hadad, Samuel Moss, et al.
BMJ Open Respiratory Research|February 11, 2026
Assessment of mosaic loss of chromosome Y in pulmonary fibrosis reveals limited association with susceptibility or disease severityDapeng Wang, Niran Hadad, Samuel Moss, et al.
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled TrialToby M Maher, Mark J Hamblin, Won-Ii Choi, et al.
Pageof 40

Showing results (261-270 of 391) with videos related to

Sort By:
Pageof 40
American Journal of Respiratory and Critical Care Medicine|June 6, 2022
Genome-wide Enrichment of <i>TERT</i> Rare Variants in Idiopathic Pulmonary Fibrosis Patients of Latino AncestryDavid Zhang, Gundula Povysil, Chad A Newton, et al.
The Lancet. Respiratory Medicine|January 18, 2024
Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trialZhe Wu, Lisa G Spencer, Winston Banya, et al.
The European Respiratory Journal|February 22, 2020
Predictors of progression in systemic sclerosis patients with interstitial lung diseaseOliver Distler, Shervin Assassi, Vincent Cottin, et al.
BMJ Open Respiratory Research|September 14, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)Toby M Maher, Shervin Assassi, Arata Azuma, et al.
The Lancet. Respiratory Medicine|November 14, 2022
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trialToby M Maher, Veronica A Tudor, Peter Saunders, et al.
The European Respiratory Journal|March 30, 2019
In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortalityJohn A Mackintosh, Sujal R Desai, Huzaifa Adamali, et al.
BMJ Open|June 4, 2021
Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility studyClaire M Nolan, Suhani Patel, Ruth E Barker, et al.
Biorxiv : the Preprint Server for Biology|June 10, 2024
Association between mosaic loss of chromosome Y and pulmonary fibrosis susceptibility and severityDapeng Wang, Niran Hadad, Samuel Moss, et al.
BMJ Open Respiratory Research|February 11, 2026
Assessment of mosaic loss of chromosome Y in pulmonary fibrosis reveals limited association with susceptibility or disease severityDapeng Wang, Niran Hadad, Samuel Moss, et al.
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled TrialToby M Maher, Mark J Hamblin, Won-Ii Choi, et al.
Pageof 40